UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 25, 2015
AETHLON MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Nevada (State or other jurisdiction of incorporation) |
001-37487 (Commission File Number) |
13-3632859 (IRS Employer Identification Number) |
9635 Granite Ridge Drive, Suite 100 San Diego, California (Address of principal executive offices) |
92123 (Zip Code) |
Registrant’s telephone number, including area code: (858) 459-7800
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
FORWARD-LOOKING STATEMENTS
This Form 8-K and other reports filed by us from time to time with the Securities and Exchange Commission contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. When used in such filings, the words "anticipate,” "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to us or our management identify forward-looking statements. Such statements reflect our current view with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to our industry, our operations and results of operations and any businesses that we may acquire. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.
ITEM 1.01 | ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. |
On September 25, 2015, Aethlon Medical, Inc. (“we”) entered into an extension of our contract with the Defense Advanced Research Projects Agency, or DARPA, part of the Department of Defense. We originally entered into the initial contract on September 30, 2011. DARPA entered into this contract extension in order to exercise its option to continue the contract for year five, the final year of the contract.
The DARPA contract is priced on a fixed-price basis. Pursuant to the contract extension, we have the potential to earn up to $581,157 in fixed payments upon our achievement of the milestones for year five of the contract.
ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
(d) EXHIBITS | |
EXHIBIT NO. |
DESCRIPTION
|
10.1 |
DARPA Contract Extension dated September 25, 2015
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AETHLON MEDICAL, INC. | ||||
By: /s/ James B. Frakes |
||||
James B. Frakes | ||||
Dated: September 28, 2015 | Chief Financial Officer |
3
EXHIBIT INDEX
EXHIBIT NO. |
DESCRIPTION
|
10.1 |
DARPA Contract Extension dated September 25, 2015
|
4
Exhibit 10.1
N66001-11-C-4188
P00012
Page 2 of 3
SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION A - SOLICITATION/CONTRACT FORM
The total cost of this contract was increased by $581,157.00 from $5,354,839.00 to $5,935,996.00.
SECTION B - SUPPLIES OR SERVICES AND PRICES
CLIN 0011
The option status has changed from Option to Option Exercised.
CLIN 0012
The option status has changed from Option to Option Exercised.
SUBCLIN 001101 is added as follows:
001101 | Funding for Opt 4 MIPR# | ACRN | $581,157.00 |
HR0011518340 | AH |
SECTION E - INSPECTION AND ACCEPTANCE
The following Acceptance/Inspection Schedule was added for SUBCLIN 001101:
INSPECT AT | INSPECT BY | ACCEPT AT | ACCEPT BY |
N/A | N/A | N/A | Government |
SECTION G - CONTRACT ADMINISTRATION DATA
Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $581,157.00 from $5,354,839.00 to $5,935,996.00.
SUBCLIN 001101:
Funding on SUBCLIN 001101 is initiated as follows:
ACRN: AH
CIN: 130021178700011
N66001-11-C-4188
P00012
Page 3 of 3
Acctng Data: 9715160400 1320 BDL TTT20 1 5BT01C OR EADARP A255HR001151 83400200020602115E00 012199
Increase: $581,157.00
Total: $581,157.00
(End of Summary of Changes)